Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease (ESRD) worldwide. Inhibition of intrarenal renin-angiotensin system (RAS) with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) has been part of strategy to slow the progression of DKD [1, 2]. However, evidence of head-to-head trials in such populations regarding the relative efficacies of ACEIs and ARBs is very limited.
